Kwanan nan, Nantong Chanyoo sun sake yin wani ci gaba a cikin tarihi! Tare da ƙoƙarin fiye da shekara ɗaya, KDMF na farko na Chanyoo ya sami amincewa ta MFDS. A matsayin babban masana'anta na Calcium Rosuvastatin a China,muna fatan bude wani sabon babi a kasuwar Koriya.Kuma za a ƙaddamar da ƙarin samfuran a cikin ƴan shekaru masu zuwa.

Hakanan, zaku iya komawa kuma ku sami bayaninmu daga wannan rukunin yanar gizon:

https://nedrug.mfds.go.kr/pbp/CCBAC03

Calcium Rosuvastatin ya dace da maganin adjuvant na marasa lafiya da ke da hypercholesterolemia na farko (nau'in IIa, gami da heterozygous familial hypercholesterolemia) ko gauraye lipemia (nau'in IIb) lokacin cin abinci ko motsa jiki bai dace ba.Rosuvastatin calciummai zaɓin 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) mai hanawa reductase. Ta hanyar hana HMG-CoA reductase, yana rage haɗin hanta da adanar cholesterol, ta haka Rage jimlar cholesterol cholesterol (TC) da matakan ƙananan ƙwayoyin lipoprotein cholesterol (LDL-C).

Dangane da bayanan Newport, daga Yuni 30, 2018 zuwa 30 ga Yuni, 2019, tallace-tallace na duniya na shirye-shiryen calcium na rosuvastatin ya kasance dalar Amurka biliyan 3.461, raguwar shekara-shekara na 13%; Siyar da kayan albarkatun calcium na rosuvastatin a duniya sun kasance tan 151.09, karuwa a kowace shekara da kashi 14%.

Mu,Kamfanin Magunguna na Changzhou(Masana'anta na biyu: Nantong Chanyoo Pharmatech Co., Ltd.) ya sadaukar da kanmu ga babban mai samar da Rosuvastatin API.